KUALA LUMPUR, Oct 10 (Bernama) -- A new Best’s Commentary has addressed frequently asked questions (FAQ) about Best’s National Scale Ratings (NSR) and how they compare with global Best’s Credit Ratings.
Global credit rating agency, AM Best in a statement said an NSR is a relative measure of the financial strength of insurers and reinsurers that are domiciled in the same country.
The NSR focuses on local insurance market characteristics and allows for a more appropriate comparison among domestic market participants, which over time should allow for greater differentiation among them.
AM Best currently assigns NSRs in Egypt, India, Indonesia, Mexico, the Philippines and Vietnam.
The commentary also addressed other issues such as when an NSR can be assigned; how NSRs are mapped from Best’s Issuer Credit Ratings; and whether country risk can influence an NSR.
Headquartered in the United States, AM Best does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City.
-- BERNAMA
Tuesday, 10 October 2023
AM BEST RESPONDS FAQ ON NATIONAL SCALE RATINGS
Monday, 9 October 2023
VINCSS NAMED BEST IN CLASS APAC PASSWORDLESS AUTHENTICATION BY FROST & SULLIVAN
KUALA LUMPUR, Oct 9 (Bernama) -- VinCSS, a subsidiary of Vingroup has been awarded the 2023 Asia Pacific (APAC) New Product Innovation Award by Frost & Sullivan, following a research of the passwordless authentication landscape.
Based in Ho Chi Minh City, Vietnam, VinCSS stands out as a pioneer in leveraging FIDO2 standards for passwordless authentication, focuses on providing cybersecurity solutions for information technology (IT), Internet of Things (IoT), and Automotive.
“We are continuously evolving, and this accolade is a testament to our dedication. We remain, as always, the industry's trusted partner,” said VinCSS Chief Executive Officer and Founder, Simon Trac Do in a statement.
Meanwhile, Frost & Sullivan global cybersecurity industry principal, Anh Tien Vu said VinCSS sets itself apart from many competitors with a unique and innovative approach enabling customers to deploy its products across different environments while competitors only focus on addressing identity security challenges for the workforce.
Specialising in IT security, identity and access management, IoT security, automotive cybersecurity, VinCSS is consistently breaking new ground and has evolved from a startup to a leader in innovative product development and diversification within the cybersecurity industry.
VinCSS offers comprehensive passwordless authentication solutions via its FIDO2 Ecosystem, strengthening cybersecurity and bringing a significant upgrade in authentication, helping businesses follow authentication rules while making their operations more efficient.
With full control over its product lineup, VinCSS offers competitive pricing in which this strategy solidifies its leading role in the passwordless authentication market.
Beyond being a respected name in cybersecurity, VinCSS is emerging as a prime investment opportunity. As it approaches its financial break-even point and launches its Series B funding round, the company presents significant growth prospects.
-- BERNAMA
AM BEST COMMENTS ON CREDIT RATINGS OF UNION MEDICAL BENEFITS SOCIETY LIMITED
SINGAPORE, Oct 6 (Bernama-BUSINESS WIRE) -- AM Best has commented that the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Union Medical Benefits Society Limited (UniMed) (New Zealand), which were affirmed on 29 September 2023, remain unchanged following the recently announced Letter of Intent to transfer the insurance portfolio of Accuro Health Insurance Society Limited (Accuro) to UniMed. The outlook of these Credit Ratings (ratings) is stable.
Accuro, like UniMed, is a mutual company writing medical insurance in New Zealand. The proposal to undertake the portfolio transfer remains subject to a vote by Accuro members and regulatory approval by the Reserve Bank of New Zealand. Subject to receiving these confirmations, the transaction is expected to be completed during the second quarter of 2024 (the fourth quarter of UniMed’s 2024 fiscal year ending 30 June). Following the portfolio transfer, all Accuro members would become members of UniMed, with their existing cover and benefits remaining in place.As the transaction progresses, AM Best will monitor the impact on UniMed’s operations and rating fundamentals.
Saturday, 7 October 2023
AJC RELEASES 50TH YEAR OF ASEAN-JAPAN FRIENDSHIP AND COOPERATION COMMEMORATIVE VIDEO
Wednesday, 4 October 2023
Digital Identity Verification Checks Exceeds 70 Bln In 2024 - Juniper Research
KUALA LUMPUR, Oct 3 (Bernama) -- The number of digital identity verification checks will surpass 70 billion in 2024; growing 16 per cent on the previous year’s number of 61 billion, according to a new study from Juniper Research.
According to Juniper Research in a statement, this growth is being driven by businesses adopting stronger biometric verification methods to combat account takeover and card-not-present fraud.
Moreover, biometric verification methods are highly effective against these kinds of fraud, with liveness checks utilised to prevent spoofing.
The foremost experts in fintech and payments markets forecasted banking will see the largest volume of checks, with 37 billion in 2024; equating to 53 per cent of the global identity verification market.
The report found continued popularity of digital-only banks is driving this growth, as these banks by their nature are reliant on digital identity verification checks; catalysing growth across the banking sector, as traditional banks play catch-up.
Hence, identity verification vendors must partner with core banking system providers to enable services to be accessed easily, or they will lose out to better-connected competitors.
Juniper Research also highlighted the importance of passive checks, along with biometric verification, to strengthen security and improve user experience.
-- BERNAMA
Tuesday, 3 October 2023
Hai Robotics’ Innovations Address Storage Density, Performance Issues
![]() |
| Photo of HaiPick A42T-E2 (Photo: Business Wire) |
KUALA LUMPUR, Oct 2 (Bernama) -- Hai Robotics (Hai), a pioneer and leader in Autonomous Case-handling Robot (ACR) Systems, has launched the world's first telescopic Grapple Hook ACR, the HaiPick A42T-E2 and the HaiPick System 3.
According to a statement, the two new innovations address customer concerns around increasing storage density and performance at a smaller warehouse footprint.
The telescopic Grapple Hook ACR can be integrated within HaiPick System 3, creating a nexus that facilitates higher performance while delivering enhanced storage density.
“We are thrilled with the launch of the HaiPick A42T-E2. This project encapsulates our commitment to providing intelligent, flexible and efficient solutions for the modern warehousing industry, while keeping in mind the growing and dynamic needs of this market on a global scale.
“HaiPick System 3 is a high-performance and agile solution that scales alongside businesses to better achieve instantaneous customer satisfaction,” said Hai Robotics EMEA General Manager, Peter Guan.
Equipped with ChainPick technology, the HaiPick A42T-E2 features a grappling hook with a picking speed of 2.7 seconds, quickly pulling totes one after another.
Such ChainPick technology is key to enabling up to five-deep tote storage capacity, allowing shorter picking and placing time to further streamline the goods-to-person workflow.
Meanwhile, the HaiPick System 3 is the latest solution in the company’s portfolio, enabling ultra-high storage density and increasing worker efficiency up to six times.
Hai Robotics is committed to providing flexible, intelligent, and efficient warehouse automation solutions through robotics technology and artificial intelligence algorithms.
-- BERNAMA
DYADIC TO PRESENT AT INDUSTRY AND INVESTOR EVENTS IN OCTOBER
JUPITER, Fla., Oct 2 (Bernama-GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October:
Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, Singapore
Dr. Ronen Tchelet, Chief Scientific Officer
“The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics”
Wednesday, October 4, 2023, 11:00 AM – 11:30 AM
LD Mirco Main Event XVI, October 3-5, 2023
Luxe Sunset Blvd Hotel, Los Angeles, CA
Mark Emalfarb, President, and Chief Executive Officer
“Next Generation Proteins for World Health, Nutrition and Wellness”
Wednesday, October 4, 2023, 8:00 AM – 8:25 AM
World Vaccine Congress Europe, October 16-19, 2023
Fira de Barcelona Montjuic, Barcelona, Spain
Mark Emalfarb, President, and Chief Executive Officer
“Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines”
Wednesday, October 18, 2023, 11:45 AM – 12:00 PM
If you would like to connect with Dyadic’s management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
SOURCE: Dyadic International, Inc.
--BERNAMA

